Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,141 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 308 · Balance 25,141 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eidos Therapeutics, Inc.
Report date January 26, 2021 · Filed January 28, 2021
Section 16 reporting ended · disclosed 2021-01-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-01-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-28 · Gift · Disposed 500 · Balance 380,467 Row 2 · 2021-01-26 · Other · Disposed 380,467 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2028-11-05 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-26 · Disposition to issuer · Disposed 70,000 · Balance 0 F2: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock.
F2: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:47 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantCommon Stock | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0001655016-26-000006 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,141 Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:46 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantCommon Stock | 319 | $0.00 | $0.00 |
DisclosureSEC source: 0001655016-26-000004 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,833 Read SEC document |
| June 05, 2026 Filed Jun 16, 2026 22:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001655016-26-000003 · primarydocument.xml · derivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 18:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantCommon Stock | 339 | $0.00 | $0.00 |
DisclosureSEC source: 0001655016-26-000002 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,514 Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantCommon Stock | 473 | $0.00 | $0.00 |
DisclosureSEC source: 0001655016-26-000001 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,175 Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 23:04 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | PurchaseCommon Stock | 10,700 | $18.64 | $199,403.06 |
DisclosureSEC source: 0001655016-25-000007 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,702 F1 · price: The price reported in column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $18.55 to $18.65, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:29 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantCommon Stock | 728 | $0.00 | $0.00 |
DisclosureSEC source: 0001655016-25-000004 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,002 F1 · kind: Consists of restricted stock units, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. (the "Issuer") common stock, granted and released to the reporting person on October 1, 2025, as a Quarterly Retainer Award pursuant to Section 2.4 of the Issuer's Outside Director Compensation Policy, as amended. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:18 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantCommon Stock | 858 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005233 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,274 F1 · kind: Consists of restricted stock units, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. (the "Issuer") common stock, granted and released to the reporting person on July 1, 2025, as a Quarterly Retainer Award pursuant to Section 2.4 of the the Issuer's Outside Director Compensation Policy, as amended. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 23:36 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.68 | $0.00 |
DisclosureSEC source: 0001562180-25-004959 · primarydocument.xml · derivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 22:11 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantCommon Stock | 559 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002992 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,416 F1 · kind: Consists of restricted stock units granted and released to the reporting person on April 1, 2025, as a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Director Compensation Policy, as amended. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 23:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 20,594 | $0.00 Strike: $17.13 | $0.00 |
DisclosureSEC source: 0001562180-24-005021 · primarydocument.xml · derivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,594 Underlying: Common Stock · 20,594 shares Expires 2034-06-10 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 10, 2024 will become vested on the earlier of (i) June 10, 2025 or (ii) the business day prior to the 2025 annual meeting of stockholders. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | PurchaseCommon Stock | 10,857 | $9.30 | $100,958.16 |
DisclosureSEC source: 0001562180-23-008573 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,857 Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 23:30 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 22,123 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001562180-23-005178 · primarydocument.xml · derivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,123 Underlying: Common Stock · 22,123 shares Expires 2033-06-12 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 22:59 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 43,731 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0001562180-23-002584 · primarydocument.xml · derivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,731 Underlying: Common Stock · 43,731 shares Expires 2033-03-03 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest each month beginning on March 3, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 19:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,000 | Not disclosed Strike: $13.20 | Not disclosed |
DisclosureSEC source: 0000899243-21-003671 · doc4.xml · derivative · entry 3 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2028-11-05 F2 · price: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. F2 · derivative.exercise_date: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 19:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | OtherCommon Stock | 380,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-003671 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. F1 · price: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. Read SEC document |
| December 28, 2020 Filed Jan 28, 2021 19:50 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003671 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,467 Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,767 | $50.16 | $289,258.88 |
DisclosureSEC source: 0000899243-20-025694 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 377,673 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.46 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| September 16, 2020 Filed Sep 16, 2020 18:35 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 3,122 | $50.16 | $156,609.51 |
DisclosureSEC source: 0000899243-20-025364 · doc4.xml · nonDerivative · entry 3 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 383,440 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $50.015 to $50.36 per share. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 18:35 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,000 | $50.06 | $50,064.00 |
DisclosureSEC source: 0000899243-20-025364 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 386,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 18:35 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 111 | $50.00 | $5,550.00 |
DisclosureSEC source: 0000899243-20-025364 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 387,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $50.00 | $250,000.00 |
DisclosureSEC source: 0000899243-20-018813 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 387,673 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | OtherCommon Stock | 1,088 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-018110 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 392,673 F1 · kind: On February 4, 2020, the Reporting Person gifted 1,088 shares in a private transaction. The gift was rescinded on June 29, 2020. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $50.00 | $250,000.00 |
DisclosureSEC source: 0000899243-20-015413 · doc4.xml · nonDerivative · entry 4 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 391,585 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| June 02, 2020 Filed Jun 5, 2020 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GiftCommon Stock | 1,020 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015413 · doc4.xml · nonDerivative · entry 3 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 396,585 F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| June 01, 2020 Filed Jun 5, 2020 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GiftCommon Stock | 1,020 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015413 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 397,605 F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| May 31, 2020 Filed Jun 5, 2020 16:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 444 | $41.57 | $18,458.63 |
DisclosureSEC source: 0000899243-20-015413 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,294 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $50.00 | $250,000.00 |
DisclosureSEC source: 0000899243-20-014714 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 398,625 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,153 | $50.00 | $107,650.00 |
DisclosureSEC source: 0000899243-20-011341 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 403,625 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,847 | $50.00 | $142,350.00 |
DisclosureSEC source: 0000899243-20-011341 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 405,778 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 10,000 | $51.57 | $515,706.00 |
DisclosureSEC source: 0000899243-20-006941 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 408,625 F1 · price: Represents the weighted average sale price of the shares sold from $51.50 to $52.05 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| February 13, 2020 Filed Feb 19, 2020 06:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 10,000 | $54.00 | $540,000.00 |
DisclosureSEC source: 0000899243-20-005000 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 418,625 F1 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| February 04, 2020 Filed Feb 19, 2020 06:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GiftCommon Stock | 1,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-005000 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 428,625 F1 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 18:35 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 3,580 | $55.00 | $196,900.00 |
DisclosureSEC source: 0000899243-20-001337 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 430,257 F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 18:35 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 6,420 | $55.01 | $353,171.90 |
DisclosureSEC source: 0000899243-20-001337 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 433,837 F1 · price: Represents the weighted average sale price of the shares ranging from $50.00 to $55.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| December 30, 2019 Filed Jan 9, 2020 18:53 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GiftCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000901 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 440,257 F1 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| December 26, 2019 Filed Jan 9, 2020 18:53 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GiftCommon Stock | 170 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000901 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 440,357 F1 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 19:31 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 10,000 | $58.90 | $589,048.00 |
DisclosureSEC source: 0000899243-19-028617 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 440,527 F1 · price: Represents the weighted average sale price of the shares sold ranging from $58.83 to $59.41 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| November 26, 2019 Filed Dec 5, 2019 19:31 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028617 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 450,527 F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 10,000 | $56.52 | $565,218.00 |
DisclosureSEC source: 0000899243-19-028274 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 451,527 F1 · price: Represents the weighted average sale price of the shares sold ranging from $56.25 to $57.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 10,000 | $55.11 | $551,073.00 |
DisclosureSEC source: 0000899243-19-028028 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 461,527 F1 · price: Represents the weighted average sale price of the shares sold ranging from $55.01 to $55.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 10,000 | $50.26 | $502,574.00 |
DisclosureSEC source: 0000899243-19-027574 · doc4.xml · nonDerivative · entry 4 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 471,527 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: Represents the weighted average sale price of the shares ranging from $50.00 to $50.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 900 | $46.45 | $41,805.00 |
DisclosureSEC source: 0000899243-19-027574 · doc4.xml · nonDerivative · entry 3 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 481,527 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares ranging from $46.39 to $46.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,100 | $45.51 | $95,567.22 |
DisclosureSEC source: 0000899243-19-027574 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 482,427 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares ranging from $45.24 to $46.02 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,000 | $44.88 | $89,757.20 |
DisclosureSEC source: 0000899243-19-027574 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 484,527 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares ranging from $44.23 to $45.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 16:58 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2 | $36.71 | $73.42 |
DisclosureSEC source: 0000899243-19-025615 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 486,527 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 16:58 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 4,998 | $36.16 | $180,744.17 |
DisclosureSEC source: 0000899243-19-025615 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 486,529 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares ranging from $35.71 to $36.69 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $45.74 | $228,722.00 |
DisclosureSEC source: 0000899243-19-023815 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 491,527 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares ranging from $45.14 to $46.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 19:18 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,780 | $39.01 | $108,445.30 |
DisclosureSEC source: 0000899243-19-022075 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 496,527 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares ranging from $38.72 to $39.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 19:18 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,220 | $38.36 | $85,150.54 |
DisclosureSEC source: 0000899243-19-022075 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 499,307 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares ranging from $37.71 to $38.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.